Please ensure Javascript is enabled for purposes of website accessibility

This Medical Device Company Just Got a Big Boost

By Jeff Little - Updated Apr 30, 2021 at 2:35PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you like good news and support from experts, this one's for you.

When a company is making smart moves to show it can grow and expand into new markets while keeping up with the pace of technology, it often earns the attention of investors. In the case of Penumbra (PEN 1.32%), it recently led to more attention from the iShares U.S. Medical Devices ETF (IHI 0.93%).

Man in wheelchair uses virtual reality device at home.

Image source: Getty Images

On the surface

Penumbra is by no means new to the game. The company has been around since 2004, specializing in medical devices with a primary focus on interventional therapies to treat vascular conditions such as stroke and aneurysm. On its fourth quarter earnings call for 2020, the company proudly boasted consecutive quarters with record sales. Q4 revenue came in at $166.9 million, increasing about 15% from 2019. What's more is that those already fantastic results include a $5.8 million reduction due to a recall (more on that later).

Since 2015, institutional investors have increased holdings in Penumbra from 8 million shares to 55 million shares in 2020. The IHI ETF recently bet more on Penumbra, going from 0.45% asset weight to 0.68% during the first quarter of 2021. But the more appealing fact is that the difference in weight is an increase of 50%. A move like that from IHI got my attention. IHI returns have climbed consistently, averaging greater than 22% annual returns for the past 5 years running. By comparison, the S&P 1500 Healthcare benchmark index averaged 14% over that same time frame, as of March 31. Simply put, the iShare ETF is made up of winners. It includes names like Medtronic, Stryker, and Abbott Labs.

Advancements are happening

Penumbra now looks like that much more of a winner. The company recently announced a partnership with RapidAI, which will bring a cutting-edge artificial intelligence platform to combine with Penumbra's products, which should provide more accurate diagnosis and faster treatment decisions in helping patients who suffer from stroke and pulmonary embolism. Penumbra also intends to bring new technology associated with its REAL VR system to market. REAL VR is an advanced portable rehabilitation technology using virtual reality to assist patients during rehabilitation following stroke and aneurysms. REAL VR was cleared by the U.S. Food and Drug Administration (FDA) in 2019 and announced by Penumbra just 14 months ago. As President, Chairman, and CEO, Adam Elsesser, points out, "the possibility to help a huge number of people has just gotten clearer, and we remain pretty excited."

A look overseas also tells a promising story. The international segment performed well during the quarter, highlighted by a new multi-year agreement with Genesis MedTech Group, the largest domestic company in China's neurovascular space, which will result in five new products from which each will produce revenue streams in licensing, royalties, and product distribution.

In addition to progress in China, continued growth is also expected in other regions across the globe, including Europe, Latin America, and Asia Pacific -- led by strong growth projected in Japan -- for 2021 and beyond.

Not all is perfect

If there is one main obstacle the healthcare company has been facing, dating all the way back to 2011, it's recalls. The most recent recall took place in December, when Penumbra issued what was called an urgent voluntary recall of the JET 7 Catheters with Xtra Flex Technology, due to risk of unexpected death or serious injury. The company noted during the fourth quarter earnings call that, following the recall, some physicians switched to other Penumbra products, while some who had moved to other companies' products have since come back to Penumbra. As previously mentioned, a reduction of $5.8 million in revenue was attributed to the recall.

The company is also facing the challenge of 2021 being what it calls a transition year for the REAL VR technology, during which time the company is not counting on huge revenue contributions from the new tech.

Taking an early plunge may pay off

Notwithstanding the challenges of rebuilding trust in one of its products and further rollout of new products, I think Penumbra has a bright future. It ended 2020 with $265 million in cash and cash equivalents, and no debt. 2021 guidance calls for 20% to 22% revenue growth over full year 2020. Perhaps that number could be higher depending on how quickly developments play out with the REAL VR platform.

As Adam Elsesser points out, the benefits of virtual reality are significant already. Now the company plans to build on the data and to "work with some of the foremost VR experts in healthcare to develop applications and clinical evidence for the REAL VR platform." If the REAL VR platform does play a significant role, as intended, now could be a great time for investors to take note of Penumbra, much like the iShares U.S. Medical Device ETF recently did.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Penumbra, Inc. Stock Quote
Penumbra, Inc.
$130.25 (1.32%) $1.70
iShares Trust - iShares U.S. Medical Devices ETF Stock Quote
iShares Trust - iShares U.S. Medical Devices ETF
$50.78 (0.93%) $0.47

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.